These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1845120)

  • 1. Induction of anti-HIV-1 immune responses by retroviral vectors.
    Jolly DJ; Warner JF
    Biotechnol Ther; 1991; 2(1-2):179-93. PubMed ID: 1845120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accell particle-mediated DNA immunization elicits humoral, cytotoxic, and protective immune responses.
    Haynes JR; Fuller DH; Eisenbraun MD; Ford MJ; Pertmer TM
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S43-5. PubMed ID: 7865332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of HIV-specific CTL and antibody responses in mice using retroviral vector-transduced cells.
    Warner JF; Anderson CG; Laube L; Jolly DJ; Townsend K; Chada S; St Louis D
    AIDS Res Hum Retroviruses; 1991 Aug; 7(8):645-55. PubMed ID: 1931234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA inoculation induces protective in vivo immune responses against cellular challenge with HIV-1 antigen-expressing cells.
    Wang B; Merva M; Dang K; Ugen KE; Boyer J; Williams WV; Weiner DB
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S35-41. PubMed ID: 7865331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic T lymphocyte and antibody responses generated in rhesus monkeys immunized with retroviral vector-transduced fibroblasts expressing human immunodeficiency virus type-1 IIIB ENV/REV proteins.
    Laube LS; Burrascano M; Dejesus CE; Howard BD; Johnson MA; Lee WT; Lynn AE; Peters G; Ronlov GS; Townsend KS
    Hum Gene Ther; 1994 Jul; 5(7):853-62. PubMed ID: 7981310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A qualitative progression in HIV type 1 glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine.
    Fuller DH; Haynes JR
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1433-41. PubMed ID: 7888198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric HIV-1 virus-like particles containing gp120 epitopes as a result of a ribosomal frameshift elicit Gag- and SU-specific murine cytotoxic T-lymphocyte activities.
    Tobin GJ; Li GH; Fong SE; Nagashima K; Gonda MA
    Virology; 1997 Sep; 236(2):307-15. PubMed ID: 9325238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epitope specificity of MHC restricted cytotoxic T lymphocytes induced by candidate HIV-1 vaccine.
    Johnson RP; Hammond SA; Trocha A; Siliciano RF; Walker BD
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S73-5. PubMed ID: 7532425
    [No Abstract]   [Full Text] [Related]  

  • 11. Cytotoxic T lymphocyte and helper T cell responses following HIV polynucleotide vaccination.
    Shiver JW; Perry HC; Davies ME; Freed DC; Liu MA
    Ann N Y Acad Sci; 1995 Nov; 772():198-208. PubMed ID: 8546393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic T cell repertoire selection. A single amino acid determines alternative class I restriction.
    Bergmann CC; Tong L; Cua RV; Sensintaffar JL; Stohlman SA
    J Immunol; 1994 Jun; 152(12):5603-12. PubMed ID: 7515908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120.
    AIDS Vaccine Evaluation Group 022 Protocol Team
    J Infect Dis; 2001 Feb; 183(4):563-70. PubMed ID: 11170981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
    Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
    J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designed recombinant adenovirus type 5 vector induced envelope-specific CD8(+) cytotoxic T lymphocytes and cross-reactive neutralizing antibodies against human immunodeficiency virus type 1.
    Ura T; Yoshida A; Xin KQ; Yoshizaki S; Yashima S; Abe S; Mizuguchi H; Okuda K
    J Gene Med; 2009 Feb; 11(2):139-49. PubMed ID: 19065543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
    Jiang W; Ren L; Jin N
    J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of retroviral vectors for the analysis of SIV/HIV-specific CD8 T cell responses.
    Negri DR; Buffa V; Leone P; Bona R; Borghi M; Carlini F; De Angelis F; Indraccolo S; Ensoli B; Cara A
    J Immunol Methods; 2004 Aug; 291(1-2):153-63. PubMed ID: 15345313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
    Akerblom L; Nara P; Dunlop N; Putney S; Morein B
    Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.